Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Go back to Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics| Gilead Sciences (NASDAQ: GILD) | Delayed: 143.44 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.44 | 52 Week High | $108.63 | |||
| Open | $143.44 | 52 Week Low | $71.39 | |||
| Day High | $143.44 | P/E | 79.25 | |||
| Day Low | $143.44 | EPS | $1.81 | |||
| Volume | 1,969 | |||||
| (NASDAQ: JNCE) | Delayed: 1.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.88 | 52 Week High | $ | |||
| Open | $13.36 | 52 Week Low | $ | |||
| Day High | $1.88 | P/E | N/A | |||
| Day Low | $1.88 | EPS | $ | |||
| Volume | 325,016 | |||||
